BEVACIZUMAB FOR THE TREATMENT OF METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS

被引：1
|
作者：
Fortune-Greeley, A. [1 ]
Cornell, P. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72147-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A34 / A34
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer
    Franken, M. D.
    van Rooijen, E. M.
    May, A. M.
    Koffijberg, H.
    van Tinteren, H.
    Mol, L.
    ten Tije, A. J.
    Creemers, G. J.
    van der Velden, A. M. T.
    Tanis, B. C.
    Groot, C. A. Uyl-de
    Punt, C. J. A.
    Koopman, M.
    van Oijen, M. G. H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 204 - 212
  • [32] Economic and cost-effectiveness issues in breast cancer treatment
    Hillner, BE
    [J]. SEMINARS IN ONCOLOGY, 1996, 23 (01) : 98 - 104
  • [33] An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer
    Gogate, Anagha
    Rotter, Jason S.
    Trogdon, Justin G.
    Meng, Ke
    Baggett, Christopher D.
    Reeder-Hayes, Katherine E.
    Wheeler, Stephanie B.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (02) : 343 - 355
  • [34] Cost-effectiveness of pertuzumab in HER2+metastatic breast cancer
    Qian, Y.
    Durkee, B. Y.
    Pollom, E. L.
    King, M.
    Dudley, S. A.
    Shaffer, J. B.
    Chang, D. T.
    Gibbs, I. C.
    Goldhaber-Fiebert, J. D.
    Horst, K. C.
    [J]. CANCER RESEARCH, 2016, 76
  • [35] TRASTUZUMAB IN METASTATIC BREAST CANCER: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES
    Andrade, T. S. D.
    Mosegui, G. B. G.
    Miranda, E. S.
    Souza, T. F. G. D.
    Vianna, C. M. D. M.
    Silva, F. V. C.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A687 - A687
  • [36] Cost-Effectiveness of Genexol-PM for Treating Metastatic Breast Cancer
    Kim, Jinhyun
    Shin, Sangjin
    [J]. JOURNAL OF BREAST CANCER, 2010, 13 (01) : 104 - 110
  • [37] REVIEWING THE COST-EFFECTIVENESS OF CHEMOTHERAPY AND TARGETED THERAPY FOR METASTATIC BREAST CANCER
    Pouwels, X. G.
    Ramaekers, B. L.
    Joore, M. A.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A703 - A703
  • [38] COST-EFFECTIVENESS OF LAPATINIB IN METASTATIC BREAST CANCER: A MIDDLE INCOME PERSPECTIVE
    Stander, M.
    Miller-Janson, H. E.
    Bergh, M.
    Pienaar, R.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A143 - A143
  • [39] An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer
    Anagha Gogate
    Jason S. Rotter
    Justin G. Trogdon
    Ke Meng
    Christopher D. Baggett
    Katherine E. Reeder-Hayes
    Stephanie B. Wheeler
    [J]. Breast Cancer Research and Treatment, 2019, 174 : 343 - 355
  • [40] Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
    Hashemi-Meshkini, Amir
    Keshavarz, Khosro
    Gharibnaseri, Zahra
    Kheirandish, Mehrnaz
    Kebriaeezadeh, Abbas
    Nikfar, Shekoufeh
    Abdollahi, Mohammad
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2013, 9 (03) : 472 - 478
12345